Pharma News

ST-266 by Noveome Biotherapeutics for Chronic Traumatic Encephalopathy (CTE): Likelihood of Approval


GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ST-266 overview

ST-266 is under development for the treatment of ocular hypertension, radiation-induced dermatitis, dry eye syndrome, periodontitis and optic neuritis, the most common presenting sign of multiple sclerosis (MS), necrotizing enterocolitis, cataract surgery complications (ophthalmology), erythema, glaucoma, Trigeminal Neuralgia (Tic Douloureux), chronic traumatic encephalopathy (CTE), diabetic retinopathy, diabetic macular edema. The drug candidate is administered through ophthalmic, topical, intraocular, buccal, nasal and lingual routes of administration. It is an amniotic membrane derived cellular cytokine solution (ACCS). It is developed based on a proprietary technology platform derived from human placental cells. The drug candidate was also under development for the treatment of deep burns (diabetic subjects), and partial thickness burns (non-diabetics subjects).

It is also under development for the treatment of gingivitis, allergic conjunctivitis, emphysema, cytokine storm (CS) in patients caused by the coronavirus disease (COVID-19), trauma, age-related macular degeneration (AMD), traumatic brain injury, persistent corneal epithelial defects and optic nerve/retinal diseases and injuries.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Thank you!

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

Noveome Biotherapeutics overview

Noveome Biotherapeutics formerly Stemnion, is a biopharmaceutical company advancing ST266, a multi-targeted secretome containing biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. Noveome Biotherapeutics is headquartered in Pittsburgh, Pennsylvania, the US.

For a complete picture of ST-266’s drug-specific PTSR and LoA scores, buy the report here.




Source link
#ST266 #Noveome #Biotherapeutics #Chronic #Traumatic #Encephalopathy #CTE #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *